Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Eteplirsen in Muscular Dystrophy, Duchenne: NCT03985878 Clinical Landscape Report 2026
16 October 2026
NCT03985878 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Eteplirsen in Muscular Dystrophy, Duchenne: NCT03992430 Clinical Landscape Report 2026
16 October 2026
NCT03992430 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dalcinonacog alfa in Hemophilia B: NCT03995784 Clinical Landscape Report 2026
16 October 2026
NCT03995784 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BAY-1093884 in Hemophilia B: NCT03996486 Clinical Landscape Report 2026
16 October 2026
NCT03996486 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Apadamtase alfa /Cinaxadamtase alfa in Anemia, Sickle Cell: NCT03997760 Clinical Landscape Report 2026
16 October 2026
NCT03997760 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mitapivat in Anemia, Sickle Cell: NCT04000165 Clinical Landscape Report 2026
16 October 2026
NCT04000165 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Vesleteplirsen in Muscular Dystrophy, Duchenne: NCT04004065 Clinical Landscape Report 2026
16 October 2026
NCT04004065 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nivolumab in Malignant Pleural Mesothelioma: NCT04013334 Clinical Landscape Report 2026
16 October 2026
NCT04013334 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Damoctocog Alfa Pegol in Hemophilia A: NCT04015492 Clinical Landscape Report 2026
16 October 2026
NCT04015492 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cyclosporine in Acute Chest Syndrome: NCT04018937 Clinical Landscape Report 2026
16 October 2026
NCT04018937 clinical landscape for Acute Chest Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tovinontrine in Semicircular Canal Dehiscence: NCT04053803 Clinical Landscape Report 2026
16 October 2026
NCT04053803 clinical landscape for Semicircular Canal Dehiscence: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Emicizumab in Hemophilia A: NCT04030052 Clinical Landscape Report 2026
16 October 2026
NCT04030052 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.